Department of Urology, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
BJU Int. 2021 Sep;128(3):343-351. doi: 10.1111/bju.15389. Epub 2021 May 4.
To assess trends in the incidence, disease management and survival rates for upper urinary tract urothelial carcinoma (UTUC) in the Netherlands.
Patients diagnosed with primary UTUC in the Netherlands between 1993 and 2017 were identified through the population-based Netherlands Cancer Registry (NCR). Patient and tumour characteristics, as well as information on treatment and vital status, were retrieved from the NCR. Age-standardized incidence rates were calculated, stratified by age, gender, calendar period and disease stage. Relative survival served as an approximation for cancer-specific survival.
We identified 13 314 patients with primary UTUC. The age-standardized incidence rate increased from 2.0 in 1993 to 3.2 per 100 000 person-years in 2017, without change in gender distribution. The increase in incidence held for all disease stages except organ-confined (T1-T2) disease. The most prominent increase was in superficial (Tis/Ta) and metastatic (M+) UTUC, which increased from 0.6 to 1.2 and 0.1 to 0.4 per 100 000 person-years, respectively. The 5-year relative survival did not change over time: 57.0% (95% confidence interval 55.9-58.1). Applied treatments were largely the same over the study period, although fewer radical nephroureterectomies and more kidney-sparing surgeries were performed in the most recent years. The use of peri-operative intravesical chemotherapy modestly increased.
Between 1993 and 2017, the age-standardized incidence of primary UTUC in the Netherlands has increased by more than 50%, but the relative survival of UTUC patients remained unchanged. Preventive measures against exposure to risk factors, early detection of disease, and more efficacious treatment methods are needed to improve outcomes of patients with UTUC.
评估荷兰上尿路尿路上皮癌(UTUC)的发病率、疾病管理和生存率趋势。
通过基于人群的荷兰癌症登记处(NCR),确定了 1993 年至 2017 年间在荷兰诊断为原发性 UTUC 的患者。从 NCR 中检索了患者和肿瘤特征,以及治疗和生存状况信息。按年龄、性别、日历期和疾病分期计算年龄标准化发病率。相对生存率是对癌症特异性生存率的近似值。
我们确定了 13314 例原发性 UTUC 患者。年龄标准化发病率从 1993 年的 2.0 上升到 2017 年的每 100000 人年 3.2,性别分布没有变化。除了器官局限(T1-T2)疾病外,所有疾病分期的发病率都有所增加。最显著的增加发生在上尿路(Tis/Ta)和转移性(M+)UTUC,从每 100000 人年 0.6 上升到 1.2 和从 0.1 上升到 0.4。5 年相对生存率在不同时期没有变化:57.0%(95%置信区间 55.9-58.1)。在研究期间,应用的治疗方法基本相同,尽管最近几年根治性肾输尿管切除术减少,保肾手术增多。围手术期膀胱内化疗的使用略有增加。
1993 年至 2017 年间,荷兰原发性 UTUC 的年龄标准化发病率增加了 50%以上,但 UTUC 患者的相对生存率保持不变。需要采取预防措施,避免接触危险因素,早期发现疾病,并采用更有效的治疗方法,以改善 UTUC 患者的预后。